157 related articles for article (PubMed ID: 34189608)
21. A multicenter observational study on Medication-Related Osteonecrosis of the Jaw (MRONJ) in advanced cancer and myeloma patients of a cancer network in North-Western Italy.
Fusco V; Cabras M; Erovigni F; Dell'Acqua A; Arduino PG; Pentenero M; Appendino P; Basano L; Ferrera FD; Fasciolo A; Caka M; Migliario M
Med Oral Patol Oral Cir Bucal; 2021 Jul; 26(4):e466-e473. PubMed ID: 33340073
[TBL] [Abstract][Full Text] [Related]
22. Factors affecting development of medication-related osteonecrosis of the jaw in cancer patients receiving high-dose bisphosphonate or denosumab therapy: Is tooth extraction a risk factor?
Soutome S; Hayashida S; Funahara M; Sakamoto Y; Kojima Y; Yanamoto S; Umeda M
PLoS One; 2018; 13(7):e0201343. PubMed ID: 30048523
[TBL] [Abstract][Full Text] [Related]
23. Oral risk factors associated with medication-related osteonecrosis of the jaw in patients with cancer.
Ueda N; Aoki K; Shimotsuji H; Nakashima C; Kawakami M; Imai Y; Kirita T
J Bone Miner Metab; 2021 Jul; 39(4):623-630. PubMed ID: 33420576
[TBL] [Abstract][Full Text] [Related]
24. Actinomyces and MRONJ: A retrospective study and a literature review.
Cerrato A; Zanette G; Boccuto M; Angelini A; Valente M; Bacci C
J Stomatol Oral Maxillofac Surg; 2021 Nov; 122(5):499-504. PubMed ID: 32827811
[TBL] [Abstract][Full Text] [Related]
25. The effect of concentrated growth factor (CGF) in the surgical treatment of medication-related osteonecrosis of the jaw (MRONJ) in osteoporosis patients: a randomized controlled study.
Yüce MO; Adalı E; Işık G
Clin Oral Investig; 2021 Jul; 25(7):4529-4541. PubMed ID: 33392802
[TBL] [Abstract][Full Text] [Related]
26. Clinical considerations for medication-related osteonecrosis of the jaw: a comprehensive literature review.
Kawahara M; Kuroshima S; Sawase T
Int J Implant Dent; 2021 May; 7(1):47. PubMed ID: 33987769
[TBL] [Abstract][Full Text] [Related]
27. Fluorescence-guided surgery for the treatment of medication-related osteonecrosis of the jaw: A prospective cohort study.
Otto S; Ristow O; Pache C; Troeltzsch M; Fliefel R; Ehrenfeld M; Pautke C
J Craniomaxillofac Surg; 2016 Aug; 44(8):1073-80. PubMed ID: 27263757
[TBL] [Abstract][Full Text] [Related]
28. Is teriparatide therapy effective for medication-related osteonecrosis of the jaw? A systematic review and meta-analysis.
Dos Santos Ferreira L; Abreu LG; Calderipe CB; Martins MD; Schuch LF; Vasconcelos ACU
Osteoporos Int; 2021 Dec; 32(12):2449-2459. PubMed ID: 34331067
[TBL] [Abstract][Full Text] [Related]
29. The Prevention of Medication-related Osteonecrosis of the Jaw.
Poxleitner P; Engelhardt M; Schmelzeisen R; Voss P
Dtsch Arztebl Int; 2017 Feb; 114(5):63-69. PubMed ID: 28241916
[TBL] [Abstract][Full Text] [Related]
30. A population based study of multiple myeloma patients with medication-related osteonecrosis of the jaw.
Auzina D; Slaidina A; Sevastjanova M; Erts R; Lejnieks A; Lejniece S
Stomatologija; 2019; 21(1):13-17. PubMed ID: 31619658
[TBL] [Abstract][Full Text] [Related]
31. [Position paper on medication-related osteonecrosis of the jaw (MRONJ)].
Svejda B; Muschitz Ch; Gruber R; Brandtner Ch; Svejda Ch; Gasser RW; Santler G; Dimai HP
Wien Med Wochenschr; 2016 Feb; 166(1-2):68-74. PubMed ID: 26847441
[TBL] [Abstract][Full Text] [Related]
32. "Spontaneous" medication-related osteonecrosis of the jaw; two case reports and a systematic review.
Khominsky A; Lim M
Aust Dent J; 2018 Dec; 63(4):441-454. PubMed ID: 30144095
[TBL] [Abstract][Full Text] [Related]
33. Multiple myeloma and chemical maxillary osteonecrosis. Can both occur simultaneously?
Junquera S; Álvarez-Yagüe E; Junquera L; Ugalde R; Rúa L
J Stomatol Oral Maxillofac Surg; 2020 Nov; 121(5):523-526. PubMed ID: 31863926
[TBL] [Abstract][Full Text] [Related]
34. The effect of chronic dental inflammation on development of Stage 0 medication-related osteonecrosis of the jaw.
Topaloglu G; Koseoglu OT; Karaca C; Kosemehmetoglu K
J Craniomaxillofac Surg; 2017 Aug; 45(8):1158-1164. PubMed ID: 28601298
[TBL] [Abstract][Full Text] [Related]
35. Surgical therapy for medication-related osteonecrosis of the jaw in osteoporotic patients treated with antiresorptive agents.
Hauer L; Jambura J; Hrusak D; Chalupova M; Posta P; Rusnak S; Vyskocil V
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2020 Mar; 164(1):100-107. PubMed ID: 30647474
[TBL] [Abstract][Full Text] [Related]
36. High C-Terminal Cross-Linking Telopeptide Levels Are Associated With a Minimal Risk of Osteonecrosis of the Jaws in Patients Taking Oral Bisphosphonates and Having Exodontia.
Friedlander AH; Chang TI; Hazboun RC; Garrett NR
J Oral Maxillofac Surg; 2015 Sep; 73(9):1735-40. PubMed ID: 25863230
[TBL] [Abstract][Full Text] [Related]
37. Quantitative assessment of mandibular bone marrow using computed tomography texture analysis for detect stage 0 medication-related osteonecrosis of the jaw.
Ito K; Muraoka H; Hirahara N; Sawada E; Hirohata S; Otsuka K; Okada S; Kaneda T
Eur J Radiol; 2021 Dec; 145():110030. PubMed ID: 34798536
[TBL] [Abstract][Full Text] [Related]
38. Osteonecrosis of the jaw in patients with inflammatory bowel disease treated with tumour necrosis factor alpha inhibitors.
Brijs K; Miclotte I; Vermeire S; Darche V; Politis C
Int J Oral Maxillofac Surg; 2020 Mar; 49(3):317-324. PubMed ID: 31466830
[TBL] [Abstract][Full Text] [Related]
39. Role of microbiological culture and polymerase chain reaction (PCR) of actinomyces in medication-related osteonecrosis of the jaw (MRONJ).
Panya S; Fliefel R; Probst F; Tröltzsch M; Ehrenfeld M; Schubert S; Otto S
J Craniomaxillofac Surg; 2017 Mar; 45(3):357-363. PubMed ID: 28162845
[TBL] [Abstract][Full Text] [Related]
40. Recurrence-Related Factors of Medication-Related Osteonecrosis of the Jaw: A Five-Year Experience.
Chen S; Ren H; He Y; An J; Zhang Y
J Oral Maxillofac Surg; 2021 Dec; 79(12):2472-2481. PubMed ID: 34481810
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
